NCT04031872 2025-09-05
LY3200882 and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer (EORTC1615)
The Netherlands Cancer Institute
Phase 1/2 Withdrawn
The Netherlands Cancer Institute
Thomas Jefferson University
ImmunityBio, Inc.
ImmunityBio, Inc.
ImmunityBio, Inc.
ImmunityBio, Inc.
ImmunityBio, Inc.
ImmunityBio, Inc.
Korean Cancer Study Group
University of Texas Southwestern Medical Center
The Netherlands Cancer Institute
Radiation Therapy Oncology Group